Tower Research Capital LLC TRC Sells 8,936 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Tower Research Capital LLC TRC reduced its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 59.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 6,098 shares of the company’s stock after selling 8,936 shares during the period. Tower Research Capital LLC TRC’s holdings in Maravai LifeSciences were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in MRVI. Gladius Capital Management LP bought a new position in shares of Maravai LifeSciences in the fourth quarter worth $30,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Maravai LifeSciences by 96.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock worth $34,000 after acquiring an additional 1,662 shares during the period. Signaturefd LLC boosted its holdings in shares of Maravai LifeSciences by 99.9% in the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock worth $34,000 after acquiring an additional 1,681 shares during the period. Performa Ltd US LLC boosted its holdings in shares of Maravai LifeSciences by 112.4% in the fourth quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock worth $39,000 after acquiring an additional 3,175 shares during the period. Finally, Pinnacle Associates Ltd. bought a new position in shares of Maravai LifeSciences in the fourth quarter worth $69,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Price Performance

NASDAQ MRVI traded up $0.38 during trading hours on Thursday, reaching $8.80. 1,426,233 shares of the stock traded hands, compared to its average volume of 2,507,551. The company has a debt-to-equity ratio of 0.70, a current ratio of 8.00 and a quick ratio of 7.41. The stock has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $6.67. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -9.66 and a beta of 0.03. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.52 and a 1 year high of $16.62.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The company had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. On average, analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on MRVI. Royal Bank of Canada lifted their price objective on Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Stifel Nicolaus dropped their price objective on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Finally, Craig Hallum began coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.56.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.